(Bold for FDA approved)
• Orexin serves to stabilize and promote wakefulness; lemborexant binds to orexin 1 and orexin 2 receptors, blocking orexin from binding there and thus preventing it from promoting wakefulness
• Generally takes effect in less than an hour
• Sedation, headache, abnormal dreams
• Sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms (rare)
unusual
common
• Wait
• To avoid problems with memory, take lemborexant only if planning to have a full night’s sleep
• Lower the dose
• Switch to a different hypnotic
• 5 mg/night
• Tablet 5 mg, 10 mg
• Has been evaluated and found effective in trials up to 1 year
• Schedule IV drug
• No evidence of physiological dependence or withdrawal symptoms in clinical trials
• Dose adjustment not necessary
• Somnolence may be increased in patients with severe renal impairment
• Dose adjustment not necessary for mild hepatic impairment
• Initial and maximum recommended dose 5 mg/night for moderate hepatic impairment
• Not recommended for patients with severe hepatic impairment
• Not studied in patients with cardiac impairment
• Some patients may tolerate lower doses better
• Safety and efficacy have not been established
• Controlled studies have not been conducted in pregnant women
• When administered during organogenesis, the no observed adverse effect levels (NOAELs) for fetal toxicity are approximately >100 and 23 times the maximum recommended human dose (MRHD) based on AUC in rats and rabbits, respectively
• When administered during pregnancy and lactation, the NOAEL for toxicity is 93 times the MRHD based on AUC in rats
• Unknown if lemborexant is secreted in human breast milk, but all psychotropics are assumed to be secreted in breast milk
• Recommended either to discontinue drug or formula feed
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera